Cargando…
High frequency of corticosteroid and immunosuppressive therapy in patients with systemic sclerosis despite limited evidence for efficacy
INTRODUCTION: In systemic sclerosis (SSc) little evidence for the effectiveness of anti-inflammatory and immunosuppressive therapy exists. The objective of this study was to determine the extent to which SSc patients are treated with corticosteroids and immunosuppressive agents. METHODS: Data on dur...
Autores principales: | Hunzelmann, Nicolas, Moinzadeh, Pia, Genth, Ekkehard, Krieg, Thomas, Lehmacher, Walter, Melchers, Inga, Meurer, Michael, Müller-Ladner, Ulf, Olski, Thorsten M, Pfeiffer, Christiane, Riemekasten, Gabriela, Schulze-Lohoff, Eckhard, Sunderkoetter, Cord, Weber, Manfred |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2009
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2688174/ https://www.ncbi.nlm.nih.gov/pubmed/19261182 http://dx.doi.org/10.1186/ar2634 |
Ejemplares similares
-
Frequency of disease-associated and other nuclear autoantibodies in patients of the German network for systemic scleroderma: correlation with characteristic clinical features
por: Mierau, Rudolf, et al.
Publicado: (2011) -
Disease progression in systemic sclerosis-overlap syndrome is significantly different from limited and diffuse cutaneous systemic sclerosis
por: Moinzadeh, Pia, et al.
Publicado: (2015) -
Older age onset of systemic sclerosis – accelerated disease progression in all disease subsets
por: Moinzadeh, Pia, et al.
Publicado: (2020) -
The registry of the German Network for Systemic Scleroderma: frequency of disease subsets and patterns of organ involvement
por: Hunzelmann, N., et al.
Publicado: (2008) -
Pharmacology and rationale for imatinib in the treatment of scleroderma
por: Moinzadeh, Pia, et al.
Publicado: (2013)